asciminib
Sign in to saveAlso known as ABL001, ABL-001
Asciminib, sold under the brand name Scemblix, is a medication used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Asciminib is a protein kinase inhibitor.
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 449.106624
Show 7 more facts
- canonical SMILES
- C1CN(CC1O)C2=NC=C(C=C2C3=CC=NN3)C(=O)NC4=CC=C(C=C4)OC(F)(F)Cl
- chemical formula
- C₂₀H₁₈ClF₂N₅O₃
- isomeric SMILES
- C1CN(C[C@@H]1O)C2=NC=C(C=C2C3=CC=NN3)C(=O)NC4=CC=C(C=C4)OC(F)(F)Cl
- World Health Organisation international non-proprietary name
- asciminib
- subject has role
- protein kinase inhibitors
- medical condition treated
- chronic myeloid leukemia
- physically interacts with
- ABL proto-oncogene 1, non-receptor tyrosine kinase
via Wikidata · CC0
~7 min read
Encyclopedic overview
11 sectionsContents
- Medical uses
- Adverse effects
- Pharmacodynamics
- History
- CABL001X2101 Clinical Study
- ASCEMBL Clinical Study
- ASC4FIRST Clinical Study
- Society and culture
- Legal status
- References
- External links
Asciminib, sold under the brand name Scemblix, is a medication used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). Asciminib is a protein kinase inhibitor.
The most common adverse reactions include upper respiratory tract infections, musculoskeletal pain, fatigue, nausea, rash, and diarrhea. In the pooled safety population in participants with newly diagnosed and previously treated Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, the most common adverse reactions include musculoskeletal pain, rash, fatigue, upper respiratory tract infection, headache, abdominal pain, and diarrhea. The most common laboratory abnormalities include decreased lymphocyte count, decreased leukocyte count, decreased platelet count, decreased neutrophil count, and decreased calcium corrected.
Excerpted from Wikipedia’s “asciminib” article, available under the CC BY-SA 4.0 licence.